Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186461 | 0.91 | LMNA (0.52) | MAPTRAB9ANPC1LMNAKDM4E | |
| SCHEMBL10185409 | 0.88 | MEN1 (0.53) | MAPTRAB9ANPC1LMNAOPRM1 | |
| SCHEMBL10185129 | 0.87 | PARP15 (0.48) | RAB9ANPC1DGAT1 | |
| SCHEMBL10184511 | 0.87 | LMNA (0.48) | MAPTRAB9ANPC1LMNAKDM4E | |
| SCHEMBL10186409 | 0.86 | LMNA (0.49) | MAPTRAB9ANPC1LMNAKDM4E | |
| SCHEMBL10185603 | 0.86 | SMN1; SMN2 (0.48) | MAPTRAB9ANPC1LMNAKDM4E | |
| SCHEMBL10185085 | 0.85 | LMNA (0.50) | MAPTRAB9ANPC1LMNAKDM4E | |
| SCHEMBL10186419 | 0.85 | PARP15 (0.50) | DGAT1 | |
| SCHEMBL10185363 | 0.85 | L3MBTL1 (0.50) | MAPTRAB9ALMNAKDM4EOPRM1 | |
| SCHEMBL10185216 | 0.84 | L3MBTL1 (0.51) | MAPTLMNAKDM4EF10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | MAPT 2628/4885RAB9A 1660/4885NPC1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.